Free Trial
NASDAQ:OKUR

OnKure Therapeutics (OKUR) Stock Price, News & Analysis

OnKure Therapeutics logo
$16.90 +0.02 (+0.12%)
(As of 05:20 PM ET)

About OnKure Therapeutics Stock (NASDAQ:OKUR)

Key Stats

Today's Range
$16.59
$17.44
50-Day Range
N/A
52-Week Range
$9.80
$77.60
Volume
31,719 shs
Average Volume
30,781 shs
Market Capitalization
$56.45 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$37.50
Consensus Rating
Buy

Company Overview

Reneo Pharmaceuticals Inc.is a clinical stage pharmaceutical company. It is focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases. Reneo Pharmaceuticals Inc.is based in SAN DIEGO.

OnKure Therapeutics Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
64th Percentile Overall Score

OKUR MarketRank™: 

OnKure Therapeutics scored higher than 64% of companies evaluated by MarketBeat, and ranked 411th out of 975 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    OnKure Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.33, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    OnKure Therapeutics has only been the subject of 3 research reports in the past 90 days.

  • Read more about OnKure Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for OnKure Therapeutics are expected to grow in the coming year, from ($4.21) to ($3.33) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of OnKure Therapeutics is -1.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of OnKure Therapeutics is -1.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    OnKure Therapeutics has a P/B Ratio of 0.78. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about OnKure Therapeutics' valuation and earnings.
  • Short Interest

    There is no current short interest data available for OKUR.
  • Dividend Yield

    OnKure Therapeutics does not currently pay a dividend.

  • Dividend Growth

    OnKure Therapeutics does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for OKUR.
  • News Sentiment

    OnKure Therapeutics has a news sentiment score of 0.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 6 news articles for OnKure Therapeutics this week, compared to 2 articles on an average week.
  • MarketBeat Follows

    1 people have added OnKure Therapeutics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, OnKure Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    17.90% of the stock of OnKure Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    90.98% of the stock of OnKure Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about OnKure Therapeutics' insider trading history.
Receive OKUR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OnKure Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

OKUR Stock News Headlines

Head-To-Head Comparison: OnKure Therapeutics (OKUR) and Its Competitors
Watch this before it gets removed
If you missed it, my emergency election broadcast is now available - but will be removed soon
See More Headlines

OKUR Stock Analysis - Frequently Asked Questions

OnKure Therapeutics' stock was trading at $19.00 on January 1st, 2024. Since then, OKUR stock has decreased by 9.6% and is now trading at $17.17.
View the best growth stocks for 2024 here
.

OnKure Therapeutics (NASDAQ:OKUR) posted its earnings results on Thursday, November, 7th. The company reported ($1.10) earnings per share for the quarter, missing the consensus estimate of ($0.97) by $0.13.

Shares of OKUR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Company Calendar

Last Earnings
11/07/2024
Today
11/14/2024
Fiscal Year End
12/31/2024
Next Earnings (Estimated)
3/27/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:OKUR
Previous Symbol
NASDAQ:OKUR
Fax
N/A
Employees
N/A
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$37.50
High Stock Price Target
$40.00
Low Stock Price Target
$35.00
Potential Upside/Downside
+120.7%
Consensus Rating
Buy
Rating Score (0-4)
3.33
Research Coverage
3 Analysts

Profitability

Net Income
$-77,390,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$22.14 per share

Miscellaneous

Free Float
2,745,000
Market Cap
$56.75 million
Optionable
N/A
Beta
0.21
20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

This page (NASDAQ:OKUR) was last updated on 11/14/2024 by MarketBeat.com Staff
From Our Partners